Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Akari Therapeutics Plc (NASDAQ: AKTX).

Full DD Report for AKTX

You must become a subscriber to view this report.


Recent News from (NASDAQ: AKTX)

Blog Exposure - Tetraphase Pharma Announced Data Presentations from IGNITE4 Study at 28th European Congress of Clinical Microbiology and Infectious Diseases
Stock Monitor: Akari Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 16, 2018 / Active-Investors.com has just released a free research report on Tetraphase Pharma, Inc. (NASDAQ: TTPH ). If you want access to this report all you need to do is sign up now by clicki...
Source: ACCESSWIRE IA
Date: April, 16 2018 07:20
Achillion, Omeros, Ra Rx, Reata, Chemocentryx And Others In The IgA Nephropathy Space
I began this article with the intent of an Achillion Pharmaceuticals ( ACHN ) focus. However, as I learned more about each of these 5 companies, I've decided to give an equal spotlight to each. I will preface the real reason for this renal-focused article is due to my own diagnosis of IgA neph...
Source: SeekingAlpha
Date: April, 09 2018 13:39
Analysis: Positioning to Benefit within ForeScout Technologies, CommerceHub, Newtek Business Services, Credit Acceptance, Akari Therapeutics, and Brady - Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ForeScout Technologies, Inc. (NASDAQ:FSCT), CommerceHub, Inc. (NASDAQ:CH...
Source: GlobeNewswire
Date: April, 03 2018 08:25
Akari Therapeutics' (AKTX) CEO David Solomon on Q4 2017 Results - Earnings Call Transcript
Akari Therapeutics, Inc. (AKTX) Q4 2017 Earnings Conference Call March 21, 2018, 08:30 ET Executives Peter Vozzo - West Wicke Partners David Solomon - CEO Dov Elefant - CFO Analysts Tim Lugo - William Blair Madhu Kumar - B. Riley FBR Presentation Operator Good m...
Source: SeekingAlpha
Date: March, 21 2018 14:56
Akari Therapeutics reports Q4 results
Akari Therapeutics ( AKTX ) Q4 results : Revenues: $0; R&D Expense: $7.1M (+7.6%); SG&A: $3.7M (+12.1%); Operating Loss: ($10.8M) (-9.1%); Net Loss: ($9.3M) (-12.0%); Loss Per Share: ($0.01); Quick Assets: $28.1M (-36.3%). More news on: Akari Therapeutics Plc, Healthcare stocks ne...
Source: SeekingAlpha
Date: March, 21 2018 08:45
Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical Progress
Received Regulatory Clearance in Europe to Open First Clinical Trial Site for Phase III PNH Naïve Trial CAPSTONE, the Phase III Naïve PNH Trial Expected to Open in Q1 2018 Phase II PNH Trial Completed With Primary Endpoint Met Phase II aHUS Trial Initiated ...
Source: GlobeNewswire
Date: March, 21 2018 07:00
Akari Therapeutics To Report Fourth Quarter and Full Year 2017 Financial and Operational Results and Host Conference Call on March 21, 2018
NEW YORK and LONDON, March 16, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announced that the Company will ...
Source: GlobeNewswire
Date: March, 16 2018 08:00
Alexion's long-acting PNH candidate ALXN1210 on par with Soliris in late-stage study; shares up 11% premarket
Alexion Pharmaceuticals (NASDAQ: ALXN ) is up  11%  premarket on light volume in response to its announcement of successful results from a Phase 3 clinical trial assessing ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria (PNH). More news on: Alexion Pharmaceuticals...
Source: SeekingAlpha
Date: March, 15 2018 07:30
Alexion Ups Its Game With ALXN1210 SC
Alexion Pharmaceuticals ( ALXN ) a biopharmaceutical company which markets the blockbuster drug Soliris, is near the end of its journey to develop an even better version of Soliris called ALXN1210. Both Soliris (eculizumab) and ALXN1210 are antibodies which bind the complement protein C5, whic...
Source: SeekingAlpha
Date: February, 20 2018 12:23
Akari Therapeutics to Present at the Leerink Partners Global Healthcare Conference
NEW YORK and LONDON, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) (“Akari” or “the Company”), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflamm...
Source: GlobeNewswire
Date: February, 07 2018 16:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-171.89821.901.961.8827,383
2017-03-10N/A6.50N/AN/A7
2017-03-096.506.506.536.482,038
2017-03-086.586.506.586.40966,129
2017-03-076.8756.607.006.606,813

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-151003,5622.8074Cover
2018-08-1410093410.7066Cover
2018-08-131771,70710.3691Cover
2018-08-105,45416,17133.7270Cover
2018-08-093,3105,46160.6116Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AKTX.


About Akari Therapeutics Plc (NASDAQ: AKTX)

Logo for Akari Therapeutics Plc (NASDAQ: AKTX)

Not available

 

Contact Information

 

 

Current Management

  • Gur Roshwalb / CEO
  • Dov Elefant / CFO
  • Pablo Jimenez / CMO

Current Share Structure

  • Market Cap: $22,729,483 - 05/14/2018
  • Issue and Outstanding: 11,776,934 - 12/31/2016

 


Recent Filings from (NASDAQ: AKTX)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 11 2018
Notification that form 20-F will be submitted late
Filing Type: NT 20-FFiling Source: edgar
Filing Date: May, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 21 2018
Amendment to a previously filed F-3
Filing Type: F-3/AFiling Source: edgar
Filing Date: February, 21 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 06 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: February, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: January, 26 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: December, 11 2017
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: December, 08 2017

 

 


Daily Technical Chart for (NASDAQ: AKTX)

Daily Technical Chart for (NASDAQ: AKTX)


Stay tuned for daily updates and more on (NASDAQ: AKTX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AKTX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AKTX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of AKTX and does not buy, sell, or trade any shares of AKTX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/